Rapt stock news plus#

Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Zacks has released a Special Report to help you do just that, and today itвЂ™s free.

Stock Alert: Why Shares Of RAPT Therapeutics Are Surging 50 Seeking Alpha 168d. The only question is вЂњWill you get into the right stocks early when their growth potential is greatest?вЂќ RAPT Stock: The Big Study News That Has RAPT Therapeutics Rocketing 100+ RTTNews 168d. Infrastructure Stock Boom to Sweep AmericaДЄ massive push to rebuild the crumbling U.S. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 37% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. The current consensus EPS estimate is -$0.69 on $1.5 million in revenues for the coming quarter and -$2.64 on $3.17 million in revenues for the current fiscal year. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. So, the shares are expected to perform in line with the market in the near future. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.ДЄhead of this earnings release, the estimate revisions trend for Rapt Therapeutics was mixed. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Д®mpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. While Rapt Therapeutics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Rapt Therapeutics shares have added about 93.8% since the beginning of the year versus the S&P 500's gain of 24.7%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Rapt stock news